BRPI1006128A2 - derivados de sulfonamida - Google Patents

derivados de sulfonamida

Info

Publication number
BRPI1006128A2
BRPI1006128A2 BRPI1006128A BRPI1006128A BRPI1006128A2 BR PI1006128 A2 BRPI1006128 A2 BR PI1006128A2 BR PI1006128 A BRPI1006128 A BR PI1006128A BR PI1006128 A BRPI1006128 A BR PI1006128A BR PI1006128 A2 BRPI1006128 A2 BR PI1006128A2
Authority
BR
Brazil
Prior art keywords
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
BRPI1006128A
Other languages
English (en)
Inventor
Brian Edward Marron
Christopher William West
Crhistopher John Markworth
David Simon Millan
David James Rawson
Kosuke Sasaki
Michael Christopher Laufersweiler
Nigel Alan Swain
Paul Anthony Stupple
Robert Ian Storer
Serge Beaudoin
Shulan Zhou
Steven Michael Reister
Original Assignee
Cagen Inc
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1006128(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cagen Inc, Pfizer Ltd filed Critical Cagen Inc
Publication of BRPI1006128A2 publication Critical patent/BRPI1006128A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C07D263/50—Benzene-sulfonamido oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
BRPI1006128A 2009-01-12 2010-01-06 derivados de sulfonamida BRPI1006128A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14392009P 2009-01-12 2009-01-12
US24572609P 2009-09-25 2009-09-25
US25876009P 2009-11-06 2009-11-06
PCT/IB2010/050033 WO2010079443A1 (en) 2009-01-12 2010-01-06 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BRPI1006128A2 true BRPI1006128A2 (pt) 2016-11-01

Family

ID=41818828

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006128A BRPI1006128A2 (pt) 2009-01-12 2010-01-06 derivados de sulfonamida

Country Status (42)

Country Link
US (3) US8153814B2 (pt)
EP (1) EP2385938B1 (pt)
JP (1) JP5053459B2 (pt)
KR (1) KR101345497B1 (pt)
CN (1) CN102348697B (pt)
AP (1) AP2811A (pt)
AR (1) AR075005A1 (pt)
AU (1) AU2010204118B2 (pt)
BR (1) BRPI1006128A2 (pt)
CA (1) CA2747419C (pt)
CL (1) CL2011001658A1 (pt)
CO (1) CO6400220A2 (pt)
CR (1) CR20110370A (pt)
CU (1) CU24099B1 (pt)
DK (1) DK2385938T3 (pt)
DO (1) DOP2011000218A (pt)
EA (1) EA020460B1 (pt)
EC (1) ECSP11011198A (pt)
ES (1) ES2536191T3 (pt)
GE (1) GEP20135992B (pt)
GT (1) GT201100195A (pt)
HK (1) HK1161253A1 (pt)
HN (1) HN2010000084A (pt)
HR (1) HRP20150355T1 (pt)
HU (1) HUE025013T2 (pt)
IL (1) IL213517A (pt)
MA (1) MA32965B1 (pt)
MX (1) MX2011007424A (pt)
MY (1) MY157017A (pt)
NI (1) NI201100137A (pt)
NZ (1) NZ593473A (pt)
PE (2) PE20120008A1 (pt)
PL (1) PL2385938T3 (pt)
PT (1) PT2385938E (pt)
RS (1) RS53941B1 (pt)
SV (1) SV2011003970A (pt)
TN (1) TN2011000316A1 (pt)
TW (2) TWI494317B (pt)
UA (1) UA105911C2 (pt)
UY (1) UY32379A (pt)
WO (1) WO2010079443A1 (pt)
ZA (1) ZA201105530B (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009235634B8 (en) * 2008-04-08 2013-05-23 Grunenthal Gmbh Substituted sulfonamide derivatives
KR101345497B1 (ko) * 2009-01-12 2013-12-31 이카겐, 인코포레이티드 설폰아미드 유도체
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP3590925B1 (en) * 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
CN103492575A (zh) 2011-01-18 2014-01-01 安姆根有限公司 NaV1.7敲除小鼠及其用途
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
BR112013025792A2 (pt) 2011-04-05 2018-04-24 Pfizer Ltd Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
CA2852796A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
BR112014010368A2 (pt) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
US20150291514A1 (en) * 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013161929A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物
WO2013161928A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014053967A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
KR102038607B1 (ko) 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
CN104869992A (zh) 2012-10-26 2015-08-26 默沙东公司 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
WO2014142221A1 (ja) 2013-03-14 2014-09-18 第一三共株式会社 呼吸器疾患用薬
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
US20160083343A1 (en) 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
PL3421462T3 (pl) 2013-06-27 2023-09-11 Pfizer Inc. Związki heteroaromatyczne i ich zastosowanie jako ligandów dopaminy d1
ES2784454T3 (es) 2013-09-09 2020-09-25 Peloton Therapeutics Inc Aril éteres y usos de los mismos
SG10201805552PA (en) * 2013-09-10 2018-08-30 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015181797A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
CR20170061A (es) 2014-07-17 2017-07-17 Chdi Foundation Inc Métodos y composiciones para el tratamiento de trastornos relacionados con vih
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
KR20180008761A (ko) 2015-05-22 2018-01-24 제넨테크, 인크. 치환된 벤즈아미드 및 이의 이용 방법
US9932304B2 (en) * 2015-06-16 2018-04-03 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
WO2017058821A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
JPWO2017078123A1 (ja) * 2015-11-06 2018-09-13 第一三共株式会社 ジメトキシベンジル基の脱離方法
CN108349963B (zh) * 2015-11-13 2021-03-30 株式会社大熊制药 钠通道阻断剂
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3386591B1 (en) 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
US10538523B2 (en) 2015-12-10 2020-01-21 Pfizer Limited 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
WO2017153952A1 (en) * 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
CN106397426A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1，3，4-噻二唑类化合物及其制备方法
CN106397425A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1,3,4-噻二唑类化合物及其制备方法
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
TN2018000385A1 (en) 2016-05-20 2020-06-15 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
WO2017202376A1 (zh) * 2016-05-26 2017-11-30 南京明德新药研发股份有限公司 磺酰胺衍生物
MA46546A (fr) * 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
TN2019000175A1 (en) * 2016-12-09 2020-10-05 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
EP3601262B1 (en) * 2017-03-23 2022-11-09 Aurigene Discovery Technologies Limited Process for the preparation of a sulfonamide structured kinase inhibitor
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
TW201920107A (zh) * 2017-08-31 2019-06-01 日商拉夸里亞創藥股份有限公司 作為ttx-s阻斷劑之雙芳氧基衍生物
EP3759098A1 (en) * 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
MX2020013317A (es) 2018-06-13 2021-04-13 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
DK3830092T3 (en) 2018-08-03 2023-08-07 Novartis Ag Heteroaromatic nmda receptor modulators and uses thereof
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
CN111285825B (zh) * 2018-12-10 2023-02-17 中国科学院上海药物研究所 一类苯磺酰胺取代的衍生物，其制法及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
US20240124406A1 (en) * 2020-06-03 2024-04-18 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
CN114073698B (zh) * 2020-08-20 2023-03-31 山西泰睿鑫科技有限公司 一种止痛止痒药物组合物及其应用方法
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
WO2023147480A1 (en) * 2022-01-28 2023-08-03 Rebel Medicine Inc Pharmaceutical compositions for treating pain

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
DE3531919A1 (de) 1985-09-07 1987-03-19 Hoechst Ag Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE3540654A1 (de) * 1985-11-13 1987-05-14 Schering Ag Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0264538A (ja) 1988-08-31 1990-03-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0532239B1 (en) 1991-09-10 1995-12-13 Zeneca Limited Benzenesulphonamide derivatives as 5-lipoxygenase inhibitors
GB2263635A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
PA8469401A1 (es) * 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
ATE245152T1 (de) * 1999-03-31 2003-08-15 Pfizer Prod Inc Dioxocyclopentylhydroxamsäure
PT1181286E (pt) * 1999-05-28 2004-02-27 Pfizer Prod Inc Hidroxamidas de acido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxilico
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
WO2001008674A1 (fr) 1999-07-29 2001-02-08 Ono Pharmaceutical Co., Ltd. Derives de sulfonamide et remedes pour l'allodynie
PT1088819E (pt) 1999-09-30 2005-09-30 Pfizer Prod Inc Derivados de 6-azauracilo como lignados de receptores da tiroide
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
AU2001258771A1 (en) 2000-05-19 2001-11-26 Takeda Chemical Industries Ltd. -secretase inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
AU2002347336A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
WO2003059265A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
JP2006506340A (ja) 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
CA2520225C (en) 2003-03-24 2014-08-12 Bayer Healthcare Ag Benzenesulfonamide derivatives
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
BRPI0413349A (pt) 2003-08-06 2006-10-10 Pfizer Prod Inc compostos de oxazol para o tratamento de doenças neurodegenerativas
PE20050358A1 (es) 2003-08-08 2005-05-16 Vertex Pharma Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
DE602004011985T2 (de) 2003-11-25 2009-03-05 Eli Lilly And Co., Indianapolis Modulatoren des peroxisomproliferatoraktivierten rezeptors
KR20060109937A (ko) * 2003-12-15 2006-10-23 니뽄 다바코 산교 가부시키가이샤 Ｎ-치환-ｎ-술포닐아미노시클로프로판 화합물 및 그의약제학적 용도
WO2005105763A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
EA011279B1 (ru) 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
MX2007001215A (es) 2004-08-06 2007-04-17 Otsuka Pharma Co Ltd Compuestos aromaticos.
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006060762A2 (en) 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2354126B1 (en) 2005-01-14 2013-09-25 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (en) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ES2340200T3 (es) 2005-09-23 2010-05-31 Pfizer Products Inc. Benzamidas sustituidas con piridinaminosulfonil como inhibidores de citromo p450 3a4 (cyp3a4).
JP2009510144A (ja) * 2005-10-06 2009-03-12 サノフィ−アベンティス ４−オキシ−ｎ−［１，３，４］−チアジアゾール−２−イル−ベンゼンスルホンアミド類、それらの製造方法及びそれらの医薬品としての使用
US7842819B2 (en) * 2005-10-21 2010-11-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
AR058296A1 (es) 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
JP5089185B2 (ja) 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
US7863302B2 (en) 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
MX2008013114A (es) 2006-04-14 2008-10-21 Abbott Gmbh & Co Kg Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008045668A1 (en) 2006-10-05 2008-04-17 Janssen Pharmaceutica N.V. Heterocyclic derived metalloprotease inhibitors
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
PL2076508T3 (pl) 2006-10-18 2011-05-31 Pfizer Prod Inc Związki biaryloeteru mocznika
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US9422235B2 (en) * 2006-12-19 2016-08-23 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
JP2008214222A (ja) 2007-03-01 2008-09-18 Tokyo Medical & Dental Univ フェノール誘導体及びその医薬用途
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
ES2323927B1 (es) 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
US20100234386A1 (en) * 2007-05-10 2010-09-16 Chaudhari Amita Quinoxaline derivatives as pi3 kinase inhibitors
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
KR20100033418A (ko) 2007-07-30 2010-03-29 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃｃｒ9 수용체의 조절제 및 그의 사용 방법
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
AU2009236256B9 (en) 2008-04-14 2015-09-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
EP2274280A2 (en) 2008-04-16 2011-01-19 Biolipox AB Bis-aryl compounds for use as medicaments
KR101345497B1 (ko) * 2009-01-12 2013-12-31 이카겐, 인코포레이티드 설폰아미드 유도체

Also Published As

Publication number Publication date
WO2010079443A1 (en) 2010-07-15
SV2011003970A (es) 2012-01-03
MX2011007424A (es) 2011-08-12
ES2536191T3 (es) 2015-05-21
CR20110370A (es) 2011-07-21
CO6400220A2 (es) 2012-03-15
TN2011000316A1 (fr) 2012-12-17
GT201100195A (es) 2013-12-10
US20120149679A1 (en) 2012-06-14
DK2385938T3 (en) 2015-04-27
HRP20150355T1 (hr) 2015-06-19
ZA201105530B (en) 2012-12-27
CU24099B1 (es) 2015-06-30
RS53941B1 (en) 2015-08-31
KR101345497B1 (ko) 2013-12-31
TWI419897B (zh) 2013-12-21
CA2747419A1 (en) 2010-07-15
CN102348697A (zh) 2012-02-08
IL213517A (en) 2015-11-30
EP2385938B1 (en) 2015-03-04
UY32379A (es) 2010-08-31
PE20142099A1 (es) 2014-12-13
US8907101B2 (en) 2014-12-09
US20130338111A1 (en) 2013-12-19
PT2385938E (pt) 2015-06-02
AU2010204118A1 (en) 2011-07-07
AR075005A1 (es) 2011-03-02
NZ593473A (en) 2013-02-22
CN102348697B (zh) 2014-12-10
MA32965B1 (fr) 2012-01-02
HN2010000084A (es) 2011-12-05
US20100197655A1 (en) 2010-08-05
IL213517A0 (en) 2011-07-31
PL2385938T3 (pl) 2015-07-31
AP2011005788A0 (en) 2011-08-31
JP5053459B2 (ja) 2012-10-17
GEP20135992B (en) 2013-12-25
EP2385938A1 (en) 2011-11-16
HUE025013T2 (hu) 2016-04-28
JP2012515156A (ja) 2012-07-05
TWI494317B (zh) 2015-08-01
ECSP11011198A (es) 2011-10-31
KR20110104558A (ko) 2011-09-22
EA020460B1 (ru) 2014-11-28
HK1161253A1 (en) 2012-08-24
CU20110145A7 (es) 2012-02-15
CA2747419C (en) 2014-07-08
TW201422631A (zh) 2014-06-16
PE20120008A1 (es) 2012-01-24
CL2011001658A1 (es) 2011-11-11
US8541588B2 (en) 2013-09-24
TW201038586A (en) 2010-11-01
UA105911C2 (uk) 2014-07-10
DOP2011000218A (es) 2011-10-15
MY157017A (en) 2016-04-15
AP2811A (en) 2013-12-31
US8153814B2 (en) 2012-04-10
AU2010204118B2 (en) 2012-12-20
NI201100137A (es) 2011-11-02
EA201170922A1 (ru) 2012-01-30

Similar Documents

Publication Publication Date Title
BRPI1006128A2 (pt) derivados de sulfonamida
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
FI20095678A0 (fi) Ureasubstituoituja sulfoniamidijohdannaisia
DE112010004215A5 (de) Hydrostataktor
ECSP12011999A (es) Derivados benzamida sustituidos
DE112010002949A5 (de) Kupplungstastpunkte
BRPI1008774A2 (pt) espiroamida substituída
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2397480T3 (da) Diazepindionderivat
BRPI1008827A2 (pt) deisobutenizador
BR112012010519A2 (pt) derivados de sulfonamida heterocíclicos
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DE112009005323A5 (de) Hebelarmprüfmaschine
DK2387580T3 (da) Deoxyactagardinderivater
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1011416A2 (pt) derivados de antraquinova novos
DOP2011000348A (es) Construcciones casb7439
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.